Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Harvard Bioscience (HBIO) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to 0.18.

  • Harvard Bioscience's Equity Ratio fell 6376.02% to 0.18 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.18, marking a year-over-year decrease of 6376.02%. This contributed to the annual value of 0.5 for FY2024, which is 598.23% down from last year.
  • According to the latest figures from Q3 2025, Harvard Bioscience's Equity Ratio is 0.18, which was down 6376.02% from 0.2 recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Equity Ratio registered a high of 0.53 during Q4 2023, and its lowest value of 0.18 during Q3 2025.
  • For the 5-year period, Harvard Bioscience's Equity Ratio averaged around 0.46, with its median value being 0.5 (2024).
  • Its Equity Ratio has fluctuated over the past 5 years, first soared by 858.05% in 2023, then plummeted by 6402.57% in 2025.
  • Over the past 5 years, Harvard Bioscience's Equity Ratio (Quarter) stood at 0.51 in 2021, then fell by 3.29% to 0.5 in 2022, then increased by 7.07% to 0.53 in 2023, then decreased by 5.98% to 0.5 in 2024, then tumbled by 63.93% to 0.18 in 2025.
  • Its last three reported values are 0.18 in Q3 2025, 0.2 for Q2 2025, and 0.19 during Q1 2025.